Sugi Predict

Sugi Predict / Compounds / SCHEMBL2933380

SCHEMBL2933380

SCHEMBL2933380

CC(=O)N1CCOC(C)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDK1 Q15118 4/20 0.56
▸ GLRA1 P23415 1/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ VNN1 O95497 2/20 0.39
▸ CHRNB2 P17787 3/20 0.38
▸ CHRNA3 P32297 3/20 0.38
▸ CHRNA4 P43681 3/20 0.38
▸ CHRNB3 Q05901 1/20 0.38
▸ CHRNA6 Q15825 1/20 0.38
▸ CYP1A2 P05177 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ CHRNB4 P30926 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ TSHR P16473 1/20 0.35
▸ PIK3CD O00329 1/20 0.34
▸ PIK3R2 O00459 1/20 0.34
▸ PIK3CA P42336 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17776430 1.00 PDK1 (0.56) PDK1GLRA1SMN1; SMN2VNN1CHRNB2
SCHEMBL15788160 1.00 PDK1 (0.56) PDK1GLRA1SMN1; SMN2VNN1CHRNB2
Trifluoroacetic Acid SCHEMBL20398325 0.88 PDK1 (0.46) PDK1GLRA1SMN1; SMN2VNN1CHRNB2
SCHEMBL18125968 0.83 PDK1 (0.56) PDK1GLRA1SMN1; SMN2VNN1NPC1
SCHEMBL3991342 0.83 PDK1 (0.56) PDK1GLRA1SMN1; SMN2VNN1NPC1
SCHEMBL18125963 0.83 PDK1 (0.56) PDK1GLRA1SMN1; SMN2VNN1NPC1
SCHEMBL27696744 0.83 PDK1 (0.60) PDK1GLRA1SMN1; SMN2VNN1NPC1
SCHEMBL25296663 0.82 PDK1 (0.55) PDK1GLRA1SMN1; SMN2VNN1NPC1
SCHEMBL4653478 0.82 SMN1; SMN2 (0.47) PDK1GLRA1SMN1; SMN2CHRNB2CHRNA3
SCHEMBL20671818 0.82 SMN1; SMN2 (0.52) PDK1GLRA1SMN1; SMN2CYP1A2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024089049-A1 MODULATORS OF SORTILIN ACTIVITY INSUSENSE ApS (DK) 2024-05-02 — — WO disclosed
WO-2023280317-A1 BENZYLAMINO TRICYCLIC COMPOUND AND USE THEREOF 南京明德新药研发有限公司 2023-01-12 — — WO disclosed
EP-3587420-B1 TRI-CYCLE COMPOUND AND APPLICATIONS THEREOF FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) 2021-03-31 — — EP disclosed
US-10961256-B2 PRMT5 inhibitors CTXT PTY LTD (AU) 2021-03-30 — — US disclosed
WO-2020238785-A1 METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR 正大天晴药业集团股份有限公司 2020-12-03 — — WO disclosed
EP-3426640-B1 PRMT5 INHIBITORS CTXT PTY LTD (AU) 2020-11-18 — — EP disclosed
US-10779540-B2 Benzamide compounds and their use as herbicides BASF SE (DE) 2020-09-22 — — US disclosed
US-10759781-B2 Substituted guanidine derivatives UBE INDUSTRIES, LTD. (JP) 2020-09-01 — — US disclosed
WO-2020057403-A1 INDOLE DERIVATIVE AND MEDICAL APPLICATION THEREOF 北京越之康泰生物医药科技有限公司 2020-03-26 — — WO disclosed
WO-2018174650-A9 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES 재단법인 대구경북첨단의료산업진흥재단 2020-01-02 — — WO disclosed
WO-2017153513-A1 TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS CTXT PTY LIMITED (AU) 2017-09-14 — — WO disclosed
WO-2017153515-A1 TETRAHYDROISOQUINOLINES AS PRMT5-INHIBITORS CTXT PTY LIMITED (AU) 2017-09-14 — — WO disclosed
WO-2017153518-A1 PRMT5 INHIBITORS CTXT PTY LIMITED (AU) 2017-09-14 — — WO disclosed
WO-2017112777-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC (US) 2017-06-29 — — WO disclosed
WO-2016034671-A1 AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS CTXT PTY LTD (AU) 2016-03-10 — — WO disclosed
WO-2016034675-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS CTXT PTY LTD (AU) 2016-03-10 — — WO disclosed
WO-2016034673-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS CTXT PTY LTD (AU) 2016-03-10 — — WO disclosed
US-20110251379-A1 COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS SATORI PHARMACEUTICALS, INC. (US) 2011-10-13 — — US disclosed
EP-2229362-A1 PIPERAZINES AS ANTI-OBESITY AGENTS AstraZeneca AB (SE) 2010-09-22 — — EP disclosed
WO-2009071658-A1 PIPERAZINES AS ANTI-OBESITY AGENTS BIOVITRUM AB (PUBL) (SE) 2009-06-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10779540-B2 Benzamide compounds and their use as herbicides DDT, DNPH1, BBOX1 PDK1 2158/4885GLRA1 902/4885SMN1; SMN2 3108/4885
US-10759781-B2 Substituted guanidine derivatives GMPS, GUCY1A1, GUCY1A2 PDK1 3688/4885GLRA1 166/4885SMN1; SMN2 1111/4885
US-10961256-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT3 PDK1 3253/4885GLRA1 1166/4885SMN1; SMN2 1531/4885
US-20110251379-A1 COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS CLN6, NLN, ACHE PDK1 1982/4885GLRA1 3846/4885SMN1; SMN2 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.